The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Coronary interventions

Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial

EuroIntervention 2020;16:634-644. DOI: 10.4244/EIJ-D-19-00498

1. Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; 2. Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand; 3. Department of Internal Medicine, Cardiology Division, University of Campinas (UNICAMP), Campinas, Brazil; 4. Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands; 5. First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland; 6. Tiefenauspital, Bern, Switzerland; 7. University Hospital Southampton, Southampton, and Faculty of Medicine, University of Southampton, Southampton, United Kingdom; 8. Städtische Kliniken Neuss, Lukaskrankenhaus GmbH, Neuss, Germany; 9. Schwarzwald-Baar Klinikum, Villingen-Schwenningen, Germany; 10. Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark; 11. Royal Blackburn Hospital, Blackburn, United Kingdom; 12. Cardialysis B.V., Rotterdam, the Netherlands; 13. Kerckhoff Campus, University of Giessen, Bad Nauheim, Germany; 14. FACT (French Alliance for Cardiovascular Trials), Université Paris-Diderot, Paris, France; 15. Biosensors Clinical Research, Morges, Switzerland; 16. Department of Cardiology, National University of Ireland, Galway, Ireland; 17. Department of Cardiology, University of Bern, Inselspital, Bern, Switzerland; 18. Jessa Ziekenhuis, Faculty of Medicine and Life Sciences at the Hasselt University, Hasselt, Belgium

Aims: The aim of this study was to evaluate the impact of a novel antiplatelet regimen in patients with increasing total stent length (TSL).

Methods and results: This is a post hoc analysis of the GLOBAL LEADERS trial, a prospective, multicentre, open-label, randomised trial, investigating the impact of the experimental strategy (one-month dual antiplatelet therapy [DAPT] followed by 23-month ticagrelor monotherapy) versus the reference regimen (12-month DAPT followed by 12-month aspirin monotherapy) in patients with a Biolimus A9-eluting stent (BES). The primary endpoint was the composite of all-cause death and new Q-wave myocardial infarction (MI), and the secondary endpoint was Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at two years. To investigate the association between total stent length and outcomes, groups were compared in quartiles according to TSL; the fourth quartile group was at significantly higher ischaemic risk at two years. In that stratum (TSL ≥46 mm), the experimental strategy significantly reduced the risk of the primary endpoint (hazard ratio [HR] 0.67, 95% confidence interval [CI]: 0.49-0.90; pinteraction=0.043), while demonstrating a similar risk of BARC type 3 or 5 bleeding (HR 0.99, 95% CI: 0.66-1.49; pinteraction=0.975).

Conclusions: Ticagrelor monotherapy could potentially balance ischaemic and bleeding risks, thereby achieving a net clinical benefit in patients with a TSL ≥46 mm with a BES.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE-ABSORB randomised clinical trial